Nebenwirkungen der antiretroviralen Therapie
Tóm tắt
Từ khóa
Tài liệu tham khảo
Palella FJ, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study. N Engl J Med 26: 853–860
Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51–58
Constans J, Pellegrin JL, Peuchant E et al. (1994) Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 24: 416–420
Segerer S, Bogner JR, Walli R, Loch O, Goebel FD (1999) Hyperlipidemia under treatment with proteinase inhibitors. Infection 27: 77–81
Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO (2003) Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 17: 189–194
Schmitz M, Michl GM, Walli R et al. (2001) Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 26: 225–235
Pozniak AL, Staszewski S, Gallant J et al. (2002) Comparison of the efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART) after 48 weeks of treatment. 6th International Congress on Drug Therapy in HIV Infection, November 17–21, Glasgow, UK
Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP (1991) Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 40: 651–656
Walli R, Herfort O, Michl GM et al. (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12: F167–173
Brinkman K (2000) Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 31: 167–169
Flint OP, Mulvey R, Wang S, et al. (2001) Nucleoside reverse transcriptase inhibitors: inhibition of mitochondrial DNA replication, but no effect on adiposity in an obese mouse model. Antivir Ther 6 (Suppl 4): 17
Caron M, Auclair M, Kornprobst M, Capeau J (2002) Stavudine and didanosine partly reversed the adverse effects of indinavir on cell differentiation and response to insulin but enhanced apoptosis of cultured adipocytes. Antivir Ther 7: L6
Domingo P, Matias-Guiu X, Pujol RM, Francia E, Lagarda E, Sambeat MA, Vazquez G (1999) Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13: 2261–2267
Murata H, Hruz PW, Mueckler M (2000) The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275: 20251–20254
Murata H, Hruz PW, Mueckler M (2002) Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and improvements in drug therapy. Curr Drug Targets Infect Disord 2: 1–8
Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C (2001) Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15: F11–18
Behrens GM, Boerner AR, Weber K, van den Hoff J, Ockenga J, Brabant G, Schmidt RE (2002) Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110: 1319–1327
Bastard JP, Caron M, Vidal H et al. (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026–1031
Dresner A, Laurent D, Marcucci M et al. (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103: 253–259
Grinspoon SK (2003) The pathophysiology of HIV-1 related insulin resistance and dyslipemia. 10th Conference on Retroviruses and Opportunistic Infections, February 10–14, Boston, MA, USA
Capeau J (2003) Progress in understanding the pathogenesis of HIV-1 related lipodystrophy. 10th Conference on Retroviruses and Opportunistic Infections, February 10–14, Boston, MA, USA
Hruz PW, Murata H, Qiu H, Mueckler M (2002) Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51: 937–942
Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50: 1378–1388
Roche R, Poizot-Martin I, Martin-El Yazidi C, Compe E, Gastaut JA, Torresani J, Planells R (2002) Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 16: 13–20
Vigouroux C, Auclair M, Dubosclard E, Pouchelet M, Capeau J, Courvalin JC, Buendia B (2001) Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. J Cell Sci 114: 4459–4468
Jones SP, Janneh O, Maher B, Khoo S, Back DJ, Pirmohamed M (2002) Altered TNF-α and IL-6 levels and the antiadipogenic effects on cultured adipocytes: possible mechanism for their role in lipodystrophy in HIV-infected patients. Antivir Ther 7: L2
Sewter C, Berger D, Considine RV et al. (2002) Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes 51: 1035–1041
Bastard JP, Caron M, Vidal H et al. (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026–1031
van der Valk M, Bisschop PH, Romijn JA et al. (2001) Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093–2100
Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S (2002) Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51: 1143–1147
Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS (2003) Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88: 627–636
Dinges WL, Chen D, Shimomura I, Matsuzawa Y, Peterson DM, Garg A (2003) Adipocytokine levels in the lipodystrophy syndrome of HIV-infected patients. 10th Conference on Retroviruses and Opportunistic Infections, February 10–14, Boston, MA, USA
Johnson JA, Albu JB, He Q, Engelson ES, Kotler DP (2001) Elevated in vitro tumor necrosis factor α release from abdominal subcutaneous adipose tissue (sat) in HIV-Infected subjects with lipodystrophy. Antivir Ther 6 (Suppl 4): 16–17
Christeff N, Melchior JC, de Truchis P, Perronne C, Gougeon ML (2002) Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 32: 43–50
Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M (2002) TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16: 2013–2018.
Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, James I, Mallal S (2003) Tumour necrosis factor-alpha gene 238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17: 121–123
Tomlinson JW, Moore J, Cooper MS et al. (2001) Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142: 1982–1989
Renard E, Fabre J, Paris F, Reynes J, Bringer J (1999) Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 51: 223–230
Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S (2001) Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 86: 504–310
Torres RA, Unger KW, Cadman JA, Kassous JY (1999) Recombinant human growth hormone improves truncal adiposity and "buffalo humps" in HIV-positive patients on HAART. AIDS 13: 2479–2481
Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13: 2099–2103
Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP (2002) Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 30: 379–391
Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351: 1958
Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, Montanera JS (2001) Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment. AIDS 15: 231–239
Friis-Møller N, Weber R, D'Arminio Monforte A et al. (2003) Exposure to HAART Is associated with an increased risk of myocardial infarction: The D:A:D Study. 10th Conference on Retroviruses and Opportunistic Infections, February 10–14, Boston, MA, USA
Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702–710
Clumeck N, Goebel FD, Rozenbaum W et al. (2001) Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15: 1517–1526
Walli RK, Michl GM, Bogner JR, Goebel FD (2001) Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 6: 413–421
Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13: 805–810
Martinez E, Mocroft A, Garcia-Viejo MA et al. (2001) Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357: 592–598
Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S (2000) Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284: 472–477
Walli R, Michl GM, Muhlbayer D, Brinkmann L, Goebel FD (2000) Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 199: 253–262
Sutinen J, Hakkinen AM, Westerbacka J et al. (2002) Rosiglitazone in the treatment of HAART associated lipodystrophy (HAL): a randomized, double-blind, placebo-controlled study. 9th Conference on Retroviruses and Opportunistic Infections, February 24–28, Seattle, WA, USA
Gelato MC, Mynarcik DC, Quick JL et al. (2002) Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163–170